International Journal of Hematology

, Volume 80, Issue 1, pp 83–90 | Cite as

Glanzmann Thrombasthenia Associated with a 21-Amino Acid Deletion (Leu817-Gln837) in Glycoprotein IIb due to Abnormal Splicing in Exon 25

  • Tetsuro-Takahiro Fujimoto
  • Mihoko Sora
  • Kazuko Ide
  • Miyoko Mizushima
  • Masashi Mita
  • Shinichiro Nishimura
  • Kazuhiro Ueda
  • Kingo Fujimura


We report a novel genetic defect in a Japanese patient with type I Glanzmann thrombasthenia.The glycoprotein (GP) IIb complementary DNA (cDNA) from platelet messenger RNA had a 63-base pair deletion in the 5′ boundary of exon 25, resulting in an in-frame deletion of 21 amino acid residues (Leu817-Gln837) in the calf-2 domain.The deleted region was present in the genomic DNA, but the splice acceptor site (AG) of exon 25 was mutated to AC, leading to the use of an AG sequence in the middle of exon 25 as an abnormal cryptic splice acceptor site. The effect of this deletion on protein synthesis was further analyzed. Mutant GPIIb-IIIa complexes were not detected on the surfaces of cells cotransfected with cDNAs of mutant GPIIb and normal GPIIIa. Mutant pro-GPIIb was detected in cell lysates and was coimmunoprecipitated with an anti-GPIIb-IIIa complex antibody. Immunostaining demonstrated that the mutant pro-GPIIb colocalized with an endoplasmic reticulum protein, calnexin, within the cells. These results indicate that complex formation was not completely prevented and that impairment of the subsequent transport was the major reason for the defect in cell surface expression. The data suggest that the GPIIb calf-2 domain is important for intracellular transport of GPIIb-IIIa complexes.

Key words

Glanzmann thrombasthenia Platelets GPIIb-IIIa complex Intracellular transport Calf-2 domain 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood. 1998;91:2645–2657.PubMedGoogle Scholar
  2. 2.
    French DL, Seligsohn U. Platelet glycoprotein IIb/IIIa receptors and Glanzmann’s thrombasthenia. Arterioscler Thromb Vasc Biol. 2000;20:607–610.CrossRefGoogle Scholar
  3. 3.
    Tomiyama Y. Glanzmann thrombasthenia: integrin alpha IIb beta 3 deficiency. Int J Hematol. 2000;72:448–454.PubMedGoogle Scholar
  4. 4.
    Duperray A, Berthier R, Chagnon E, et al. Biosynthesis and processing of platelet GPIIb-IIIa in human megakaryocytes. J Cell Biol. 1987;104:1665–1673.CrossRefGoogle Scholar
  5. 5.
    Rosa JP, McEver RP. Processing and assembly of the integrin, glycoprotein IIb-IIIa, in HEL cells. J Biol Chem. 1989;264:12596–12603.PubMedGoogle Scholar
  6. 6.
    O’Toole TE, Loftus JC, Plow EF, Glass AA, Harper JR, Ginsberg MH. Efficient surface expression of platelet GPIIb-IIIa requires both subunits. Blood. 1989;74:14–18.PubMedGoogle Scholar
  7. 7.
    Xiong JP, Stehle T, Diefenbach B, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta 3. Science. 2001;294:339–345.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Beglova N, Blacklow SC, Takagi J, Springer TA. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol. 2002;9:282–287.CrossRefGoogle Scholar
  9. 9.
    Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002;110:599–611.CrossRefGoogle Scholar
  10. 10.
    Tomiyama Y, Kashiwagi H, Kosugi S, et al. Abnormal processing of the glycoprotein IIb transcript due to a nonsense mutation in exon 17 associated with Glanzmann’s thrombasthenia. Thromb Haemost. 1995;73:756–762.PubMedCrossRefGoogle Scholar
  11. 11.
    Heidenreich R, Eisman R, Surrey S, et al. Organization of the gene for platelet glycoprotein IIb. Biochemistry. 1990;29:1232–1244.CrossRefGoogle Scholar
  12. 12.
    Fujimoto T, Fujimura K, Noda M, Takafuta T, Shimomura T, Kuramoto A. 50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets. Blood. 1995;86:2174–2182.PubMedGoogle Scholar
  13. 13.
    Fujimoto TT, Katsutani S, Shimomura T, Fujimura K. Thrombospondin- bound integrin-associated protein (CD47) physically and functionally modifies integrin αIIbβ3 by its extracellular domain. J Biol Chem. 2003;278:26655–26665.CrossRefGoogle Scholar
  14. 14.
    Fujimoto TT, Noda M, Takafuta T, Shimomura T, Fujimura K, Kuramoto A. Expression and functional characterization of the P-selectin glycoprotein ligand-1 in various cells. Int J Hematol. 1996;64:231–239.CrossRefGoogle Scholar
  15. 15.
    Yatuv R, Rosenberg N, Zivelin A, et al. Identification of a region in glycoprotein IIIa involved in subunit association with glycoprotein IIb: further lessons from Iraqi-Jewish Glanzmann thrombasthenia. Blood. 2001;98:1063–1069.CrossRefGoogle Scholar
  16. 16.
    McEver RP, Bennett EM, Martin MN. Identification of two structurally and functionally distinct sites on human platelet membrane glycoprotein IIb-IIIa using monoclonal antibodies. J Biol Chem. 1983;258:5269–5275.PubMedGoogle Scholar
  17. 17.
    Loftus JC, Plow EF, Jennings LK, Ginsberg MH. Alternative proteolytic processing of platelet membrane glycoprotein IIb. J Biol Chem. 1988;263:11025–11028.PubMedGoogle Scholar
  18. 18.
    Kolodziej MA, Vilaire G, Gonder D, Poncz M, Bennett JS. Study of the endoproteolytic cleavage of platelet glycoprotein IIb using oligonucleotide-mediated mutagenesis. J Biol Chem. 1991;266:23499–23504.PubMedGoogle Scholar
  19. 19.
    Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost. 1994;72:1–15.PubMedGoogle Scholar
  20. 20.
    Mitchell WB, Li JH, Singh F, et al. Two novel mutations in the αIIb calcium-binding domains identify hydrophobic regions essential for αIIbβ3 biogenesis. Blood. 2003;101:2268–2276.CrossRefGoogle Scholar
  21. 21.
    Tadokoro S, Tomiyama Y, Honda S, et al. A Gln747→Pro substitution in the αIIb subunit is responsible for a moderateαIIbβ3 deficiency in Glanzmann thrombasthenia. Blood. 1998;92:2750–2758.PubMedGoogle Scholar
  22. 22.
    Gonzalez-Manchon C, Fernandez-Pinel M, Arias-Salgado EG, et al. Molecular genetic analysis of a compound heterozygote for the glycoprotein (GP) IIb gene associated with Glanzmann’s thrombasthenia: disruption of the 674-687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa complexes. Blood. 1999;93:866–875.PubMedGoogle Scholar
  23. 23.
    Iwamoto S, Nishiumi E, Kajii E, Ikemoto S. An exon 28 mutation resulting in alternative splicing of the glycoprotein IIb transcript and Glanzmann’s thrombasthenia. Blood. 1994;83:1017–1023.PubMedGoogle Scholar
  24. 24.
    Vinciguerra C, Khelif A, Alemany M, et al. A nonsense mutation in the GPIIb heavy chain (Ser 870→stop) impairs platelet GPIIb-IIIa expression. Br J Haematol. 1996;95:399–407.CrossRefGoogle Scholar
  25. 25.
    Arias-Salgado EG, Tao J, Gonzalez-Manchon C, et al. Nonsense mutation in exon-19 of GPIIb associated with thrombasthenic phenotype. Failure of GPIIb (delta597-1008) to form stable complexes with GPIIIa. Thromb Haemost. 2002;87:684–691.CrossRefGoogle Scholar
  26. 26.
    Peretz H, Rosenberg N, Usher S, et al. Glanzmann’s thrombasthenia associated with deletion-insertion and alternative splicing in the glycoprotein IIb gene. Blood. 1995;85:414–420.PubMedGoogle Scholar
  27. 27.
    Rosenberg N, Yatuv R, Sobolev V, Peretz H, Zivelin A, Seligsohn U. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus. Blood. 2003;101:4808–4815.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Tetsuro-Takahiro Fujimoto
    • 1
  • Mihoko Sora
    • 1
  • Kazuko Ide
    • 1
  • Miyoko Mizushima
    • 1
  • Masashi Mita
    • 1
  • Shinichiro Nishimura
    • 2
  • Kazuhiro Ueda
    • 2
  • Kingo Fujimura
    • 1
  1. 1.Department of Hematology and Oncology, Division of Clinical PharmacotherapeuticsProgram for Applied BiomedicineJapan
  2. 2.Department of Pediatrics, Graduate School of Biomedical SciencesHiroshima UniversityHiroshimaJapan

Personalised recommendations